Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03089645 2020-07-27

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

Phase 1 Completed

39 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02261220 2020-03-06

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

Phase 1 Completed

380 enrolled

Other solid neoplasm

Advanced Solid Tumors

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

58 enrolled

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02000947 2019-10-31

D4190C00006

Phase 1 Completed

459 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02705482 2019-08-26

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Phase 1 Completed

58 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Neoplasms

NCT02549651 2019-02-27

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Phase 1 Completed

32 enrolled

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02141347 2018-12-12

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

Phase 1 Completed

65 enrolled

Other solid neoplasmThoracic

Part A and B: Advanced Solid Malignancies

NCT02262741 2017-10-23

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Phase 1 Completed

71 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00372853 2012-06-06

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Phase 1 Completed

28 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT00431275 2012-06-06

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

Phase 1 Completed

85 enrolled

Dermatologic

Melanoma

NCT00556023 2012-06-06

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

Phase 1 Completed

37 enrolled

Gastrointestinal

Pancreatic Neoplasms

NCT00585000 2012-06-06

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma

Phase 1 Terminated

49 enrolled

Dermatologic

Melanoma

Clinical Trials

IMFINZI-subQ

CLOVER

Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

A Study of LY3022855 in Combination With Durvalumab or Tremelimumab in Participants With Advanced Solid Tumors

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

MEDI5083 Alone and in Combination With Durvalumab, Tremelimumab, and/or Docetaxel.

A Phase 1 Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Solid Tumors

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

D4190C00006

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Ph1 to Assess Safety, Tolerability of Tremelimumab/ Tremelimumab+MEDI4736 in Japanese Solid Malignancies/ Mesothelioma

A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 (Durvalumab) With Tremelimumab in Head and Neck Cancer

Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

A Phase 1 Study Testing CP-675,206 In Combination With Gemcitabine In Patients With Previously Untreated, Advanced Pancreatic Cancer

A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma